RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

Moderna's messenger RNA flu vaccine candidate has shown has shown positive results in a late-stage trial. The biotechnology company said Monday its seasonal influenza vaccine candidate, mRNA-1010, ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

ABU DHABI, 13th June, 2025 (WAM) -- Abu Dhabi Public Health Centre (ADPHC) has vaccinated nearly 300,000 people across Abu Dhabi, Al Ain Region, and Al Dhafra with the seasonal flu vaccine as part ...